United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by iA Global Asset Management Inc.

iA Global Asset Management Inc. grew its stake in United Therapeutics Co. (NASDAQ:UTHR) by 11.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,079 shares of the biotechnology company’s stock after buying an additional 311 shares during the period. iA Global Asset Management Inc.’s holdings in United Therapeutics were worth $707,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of UTHR. Raymond James & Associates boosted its stake in United Therapeutics by 5.1% during the 4th quarter. Raymond James & Associates now owns 29,474 shares of the biotechnology company’s stock worth $6,481,000 after purchasing an additional 1,420 shares during the period. Blue Trust Inc. boosted its stake in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 46 shares during the period. First Citizens Bank & Trust Co. acquired a new stake in United Therapeutics during the 4th quarter worth $420,000. State of Michigan Retirement System boosted its stake in United Therapeutics by 6.2% during the 4th quarter. State of Michigan Retirement System now owns 11,932 shares of the biotechnology company’s stock worth $2,624,000 after purchasing an additional 700 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in United Therapeutics by 354.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,437 shares of the biotechnology company’s stock worth $1,196,000 after purchasing an additional 4,240 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $44,019.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,019.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Patusky sold 1,310 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $264.35, for a total transaction of $346,298.50. The disclosure for this sale can be found here. In the last three months, insiders sold 100,884 shares of company stock worth $30,280,055. 12.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Bank of America decreased their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 15th. HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a research report on Thursday. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $326.42.

United Therapeutics Price Performance

Shares of UTHR traded up $14.50 during trading hours on Thursday, reaching $327.79. The company had a trading volume of 666,492 shares, compared to its average volume of 495,467. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The firm has a 50 day simple moving average of $306.21 and a 200-day simple moving average of $259.74. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98. The company has a market capitalization of $14.54 billion, a price-to-earnings ratio of 15.24, a PEG ratio of 1.09 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter last year, the business posted $5.24 earnings per share. The business’s revenue was up 19.8% compared to the same quarter last year. Research analysts expect that United Therapeutics Co. will post 25.59 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.